the results of the DESTINY-CRC01 trial in 2021 confirmed its antitumor effect in patients with HER2-positive metastatic colorectal cancer (mCRC) (NCT03384940) (29). This evidence concerns the gene ERBB2 and metastatic colorectal cancer.